S. Eschmann
YOU?
Author Swipe
View article: Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with<sup>223</sup>Ra: PARABO, a Prospective, Noninterventional Study
Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with<sup>223</sup>Ra: PARABO, a Prospective, Noninterventional Study Open
223Ra, a targeted α-therapy, is approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have bone metastases. In the phase 3 ALSYMPCA study, 223Ra prolonged survival and improved quality of l…
View article: Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer—A Secondary Analysis of the PET Plan Trial
Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer—A Secondary Analysis of the PET Plan Trial Open
(1) Background: The optimal chemotherapy (CHT) regimen for concurrent chemoradiation (cCRT) is not well defined. In this secondary analysis of the international randomized PET-Plan trial, we evaluate the efficacy of different CHT. (2) Meth…
View article: Symptomatic skeletal event (SSE) dynamics in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An interim review of a prospective, non-interventional study (PARABO)
Symptomatic skeletal event (SSE) dynamics in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An interim review of a prospective, non-interventional study (PARABO) Open
Background: Phase III Ra-223 study (ALSYMPCA) was conducted before the availability of abiraterone (Abi). The ongoing PARABO study will investigate the outcome of Ra-223-treated mCRPC pts in real-life clinical practice in Germany (NCT02398…
View article: Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data
Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data Open
18 F-fluoro-2-deoxy- d -glucose positron emission tomography (PET) complements conventional imaging for diagnosing and staging lung cancer. Two literature-based meta-analyses suggest that maximum standardised uptake value (SUV max ) on PET…